For Immediate Release 17 August 2007

The Medical House PLC
AIM Rule 26 Compliant Website

The Medical House PLC (“TMH” or the “Company”), (AIM:MLH) the drug delivery specialist, announces today that the information required by Rule 26 of the AIM Rules for Companies (February 2007) is available under http://www.themedicalhouse.com/financial/shareholder/rule26.asp or from the 'Shareholder Information' section of the website.

For further information:

The Medical House PLC
Ian Townsend, Chairman
Tel: 0114 261 9011
www.themedicalhouse.com

Buchanan Communications
Tim Anderson / Rebecca Skye Dietrich
Tel : 020 7466 5000

Nomura Code Securities Limited
Richard Potts Tel : 020 7776 1200

Notes to Editors:
About The Medical House
There is a growing trend in the pharmaceutical industry towards the use of needle-based disposable autoinjectors for self-injection. The “ASI” is TMH’s first autoinjector system following the development of a range of needle-free devices which are already successfully in use. TMH’s ASI autoinjector technology allows injections to be easily and safely undertaken by patients themselves or by other non-clinicians such as family members and colleagues and are applicable to both elective therapies and emergency situations.

In December 2006, TMH announced that it had entered into a development, licensing and supply agreement for the ASI with a leading global pharmaceutical partner, for delivery of an, as-yet, undisclosed drug. TMH’s revenues from this agreement, consisting of development, supply and technology access fees, are projected to be in the region of £27m over an initial five year period, with technology access fees comprising approximately £18m of these revenues.

TMH signed its first deal for the ASI in June 2006 with Martindale Products and Specials, part of Cardinal Health Inc, in an initial five-year contract to supply the ASI system for use with an, as-yet, undisclosed pharmaceutical product, in the United Kingdom. The combined product is to incorporate TMH’s ASI and Martindale’s pre-filled syringe,. The agreement has projected revenues for TMH of £3m over an initial supply period of 5 years.

In December 2005, TMH announced an agreement with a European Government Agency to develop a disposable autoinjector for emergency administration of specific pharmaceutical compounds, based on TMH’s ASI autoinjector. Within this project, TMH’s client is making the required capital investment and covering the costs of design and development. In March 2007, it was announced that TMH had been commissioned by this Agency to enter into a second phase of development within the project, which involves TMH developing and manufacturing devices, according to defined operational and functional requirements, for technical assessment, over an anticipated 12 months project duration. Within the second phase of the project, TMH will receive up to £1m, subject to achieving agreed milestones, in relation to the cost of the project including associated design and development activities.

In September 2004, TMH signed an agreement with Serono to develop and supply a new needle-free injector for use with its human growth hormone. This licence and supply agreement is for an initial period of 5 years with projected revenues for TMH of £4.3m.

In February 2005, TMH announced a 10-year agreement which it has signed with BioPartners GmbH, to supply its needle-free system for the delivery of BioPartners’ human growth hormone products.

Historically, the majority of the group’s turnover has come from its orthopaedic company, Eurocut Limited, which designs and manufactures instruments and systems used in surgical procedures for many of the world’s leading orthopaedic companies. With the increasing significance of its drug delivery division, the group is considering its options for Eurocut.